I'm pretty sure that's irrelevant and misses the point.Reply to Levinovitz on the same Twitter thread:
James
@James6939710330
Wrong, as usual. This trial launched in 9-2022. In 10-2022, POTS was given its first ICD code. Shortly after it lost rare disease designation, and the regulatory, financial, and clinical advantages that come with orphan status. That’s why it was stopped after interim analysis.
James
@James6939710330
'It remains disputed whether LC is b-cell mediated. The drug might not have worked. But to say ‘Hard to imagine a pharma company canceling a trial of a life-altering drug for a condition that affects millions of people’ is incorrect; the financial proposition changed.
.
We've discussed the interim results on here and that they suggested a lack of efficacy. Some of us have also discussed that the Sick Times has at times done a poor job at reporting on trials both here and for BC007. Some have even written E-mails to them saying that they think it is irresponsible.
I guess there's always an interpretation bias somewhere, as Levinovitz has shown us, but not everywhere. Writing articles on something based on anecdotal stories without actually discussing the data does remind me of something.
Last edited: